ROCO
4197
Market cap9mUSD
Nov 12, Last price
10.30TWD
Name
Visgeneer Inc
Chart & Performance
P/E
—
P/S
2.69
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.09%
Rev. gr., 5y
-5.30%
Revenues
116m
-21.78%
Net income
-18m
L-9.50%
CFO
-10m
L
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Visgeneer Inc. provides health solutions in the fields of medical device, cosmetics and skin care, bacterial fermentation, and cancer gene diagnostics in Europe and Asia. The company offers blood glucose and ketone, uric acid, and cholesterol monitoring systems. It also provides functional masks, such as wood pulp mask, invisible mask, black mask, pure cloth mask, and bio cellulose mask; face cream, night cream, day cream, wrinkle cream, repairing cream, whitening cream, exfoliating cream, toner, and lotions; functional essences; body lotion and spa clay mask; physical blocker, chemical blocker, and comprehensive sun protection; face wash, wash cream, cleaning cleansing mousse, cleaning cleansing gel, shampoo, and body wash; hand cream, knee cream, foot mask, hand mask, and glucosamine cream; anti-acne cream, female private cleaning lotion, skin care, skin capsules, and hair capsules; and customized skin care products. In addition, the company offers eBmonitor Blood Monitoring System, CoreSence Skincare, BOWIL Skincare, and ZeaSight EU Patent Zeaxanthin, as well as contract manufacturing services. Visgeneer Inc. was founded in 2005 and is based in Hsinchu City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||